Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial
Authors' conclusion
IDegLira proved to be safer and more effective than MDI for individuals with type 2 diabetes who had suboptimal glycaemic control, aiding in their transition from hospital to outpatient care.
Study context
- Population
- Patients with T2D in transition from hospital to outpatient setting; baseline HbA1c 103 ± 11.6 mmol/mol (11.6 ± 1.7%), age 58 ± 12.4 years (means ± SD)included in analysis
- Participants
- 64 patients
- Comparison
- Insulin degludec/liraglutide (IDegLira) vs MDI after hospital discharge
- IDegLiran = 32
- MDIn = 32reference
- Primary endpoint
- Percentage of patients with ≥1 hypoglycaemic event (>15 min with glucose <3.0 mmol/l on CGM)
- Follow-up
- First 4 weeks
Methodological detailsopen-label
- Open-label
Primary result
As reported in the abstract
≥1 hypoglycaemic event (plasma glucose <3.0 mmol/l) · first 4 weeks
P < 0.010
Further findings
| Outcome | Incidence rate ratio (95% CI) | P value | |
|---|---|---|---|
| Hypoglycaemia event densityLower with IDegLira | 15.2 (6.2–48.2) | P < 0.001 | |
| 0.050.21520Incidence rate ratio (log scale) |
TBR <3.8 mmol/l
P = 0.019
TBR <3.0 mmol/l
P = 0.008
TIR 3.8-10 mmol/l
P = 0.008
Consistency by baseline HbA1c
- Findings consistent regardless of baseline HbA1c
Original publication
Insulin DEgludec/LIraglutide versus multiple daily insulin injections in the transition from hospital to outpatient management assessed by continuous glucose monitoring: the DELI transition trial. Diabetologia. Published 4 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →